Key facts
- It has raised $300K across 1 recorded rounds; the latest was Seed Round ($300K) in Mar 2026.
- Tavra Biosciences has filed 1 Form D with the SEC, most recently Apr 2026 ($300K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Tavra Biosciences
Funding rounds
1 roundsAbout Tavra Biosciences
Operator of a stem-cell biologics company intended to provide cGMP-manufactured mesenchymal stem cells for orthopedic and regenerative medicine applications, ensuring predictable potency, safety and clinical utility. The company offers bone marrow-derived mesenchymal stem cells from young, healthy donors, enabling customers to access off-the-shelf biologics that alleviate pain, improve joint function and accelerate wound healing with verified safety, potency and transparency.
- Sector
- Healthcare
- HQ
- Plano, TX, United States
- Founded
- 2025
- Employees
- 2
- Website
- tavrabiosciences.com/
- Ownership
- Privately Held (backing)
Tavra Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tavra Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tavra Biosciences in its N-PORT filings yet. We sweep new filings monthly.